• progress_activity cloud_sync

    Reconnection to the server…

    Movim cannot talk with the server, please try again later


    • ArsTechnica


      article 34331 posts • people 708 subscribers
      assignment_ind Only publishers can publish


    • Public subscriptions

    • chevron_right

      Blue

    • chevron_right

      Miho

  • Register Login

    Movim

    chat.macaw.me


  • rss_feed
    add Follow

    ArsTechnica

    people 708 subscribers • news.movim.eu

    • chevron_right

      Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says

      news.movim.eu / ArsTechnica • 13 October 2026

    Martin Shkreli—the ex-pharmaceutical executive infamous for illegally hiking the price of a lifesaving anti-parasitic drug by more than 4,000 percent and getting a seven-year prison sentence for the fraudulent scheme he used to do it—has been under a lifetime ban from the pharmaceutical industry since 2022.

    However, according to the Federal Trade Commission and the attorneys general of seven states, Shkreli has "flagrantly and repeatedly" violated that ban nearly the entire time—allegedly by trading stock in dozens of drug companies and discussing the industry during livestreams on social media.

    On Tuesday, the FTC and the seven states asked a federal judge to hold Shkreli in contempt for the alleged violations. The states include New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia—the same states that joined the FTC in suing Shkreli in 2020 over the "elaborate anticompetitive scheme" involving the anti-parasitic drug, Daraprim. The scheme raised the price from $17.50 per pill to $750 per pill virtually overnight, while blocking generic competitors from entering the market.

    Read full article

    Comments

    • taghealth tagpharmaceutical industry tagshkreli

    • Pictures 1 image

    • visibility
  • cloud_queue

    Powered by Movim